Zobrazeno 1 - 10
of 22
pro vyhledávání: '"James Kupiec"'
Autor:
Terence Fullerton, Brendon Binneman, William David, Marielle Delnomdedieu, James Kupiec, Peter Lockwood, Jessica Mancuso, Jeffrey Miceli, Joanne Bell
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-10 (2018)
Abstract Background Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor saturation in hu
Externí odkaz:
https://doaj.org/article/cd2894dc000748f6acf781381a6cf8a7
Autor:
Terence Fullerton, William David, J.J. Miceli, Brendon Binneman, James Kupiec, Joanne Bell, Jessica Mancuso, Peter Lockwood, Marielle Delnomdedieu
Publikováno v:
Alzheimer's Research & Therapy
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-10 (2018)
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-10 (2018)
Background Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor saturation in humans at a
Autor:
Michael Borrie, James Kupiec, Kelly R. Bales, Clare B. Billing, Michael Woodward, Qinying Zhao, Jerry Yang, Jaren W. Landen, Sharon Cohen, Martin M. Bednar, Christine Alvey, Fred McCush
Publikováno v:
Clinical Neuropharmacology. 36:14-23
Objectives Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). Methods This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics
Autor:
Terence Fullerton, Jessica Mancuso, J.J. Miceli, Marielle Delnomdedieu, Peter Lockwood, James Kupiec, Joanne Bell, William David, Brendon Binneman
Publikováno v:
Alzheimer's & Dementia. 12
Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor saturation in humans at a dose of 30
Autor:
Claire Leurent, Sridhar Duvvuri, Eve H. Pickering, James Kupiec, James A. Goodman, Jerome Barakos, Derek Purcell, Ping He, Gregory Klein, Eddie Martucci, Robert C. Alexander, Scott Kellogg
Publikováno v:
Alzheimer's & Dementia. 12
Autor:
Qinying Zhao, Sadahiro Abe, Taro Ishibashi, Carol Cronenberger, Masahito Yamada, Yoko Fujimoto, Brendon Binneman, Martin M. Bednar, Izuru Miyoshi, James Kupiec, Kanae Togo
Publikováno v:
International journal of clinical pharmacology and therapeutics. 51(12)
OBJECTIVE PF-04360365 is a humanized IgG(2)Δa anti-amyloid β (Aβ) antibody designed to improve outcome in Alzheimer's disease (AD). Single doses of 0.1 - 10 mg/kg were safe and well tolerated in Western (mostly Caucasian) subjects with mild-to-mod
Autor:
Joel Ross, Qinying Zhao, James Kupiec, Martin M. Bednar, Fred McCush, Jaren W. Landen, Scot Styren, Wendy Ma, Aaron H. Burstein, Christine Alvey
Publikováno v:
Clinical neuropharmacology. 36(1)
Objective Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Aβ) monoclonal antibody designed for treatment of Alzheimer disease (AD). A single 2-hour intravenous infusion of 0.1 to 10 mg/kg was previously shown to be safe and well tolerated
Autor:
James Kupiec, Grace M. Vandal, Yifan Huang, Joanne Bell, Peter Lockwood, Thomas A. Comery, Paul Maruff
Publikováno v:
Alzheimer's & Dementia. 8
Autor:
Sridhar Duvvuri, Joanne Bell, Tracey L. Rapp, James P. Mancuso, Grace M. Vandal, Anna Plotka, James Kupiec, Hifan Huang, Clare B. Billing, David Raunig, Claire Leurent
Publikováno v:
Alzheimer's & Dementia. 8
Autor:
Brendon Binneman, Pam Schwartz, Niels Andreasen, Carol Cronenberger, Catherine Sattler, Martin M. Bednar, James Kupiec, Henrik Östlund, Anne Börjesson-Hanson, Jaren W. Landen
Publikováno v:
Alzheimer's & Dementia. 8